Martina B Michel-Reher
Overview
Explore the profile of Martina B Michel-Reher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michel M, Michel-Reher M, Hein P
Cells
. 2020 Aug;
9(9).
PMID: 32825009
As many, if not most, ligands at G protein-coupled receptor antagonists are inverse agonists, we systematically reviewed inverse agonism at the nine adrenoceptor subtypes. Except for β-adrenoceptors, inverse agonism has...
2.
Okeke K, Michel-Reher M, Gravas S, Michel M
Front Pharmacol
. 2019 Jul;
10:596.
PMID: 31263412
β-Adrenoceptors couple not only to cAMP formation but, at least in some cell types, also to alternative signaling pathways such as phosphorylation of extracellular signal-regulated kinase (ERK). β-Adrenoceptor agonists are...
3.
Heijman J, Kirchner D, Kunze F, Chretien E, Michel-Reher M, Voigt N, et al.
Int J Cardiol
. 2018 Jan;
255:61-68.
PMID: 29290419
Background: Basal and acetylcholine-gated inward-rectifier K-currents (I and I, respectively) are altered in atrial fibrillation (AF). G-protein-coupled muscarinic (M) receptors type-2 are considered the predominant receptors activating I. Although a...
4.
Okeke K, Michel-Reher M, Michel M
Naunyn Schmiedebergs Arch Pharmacol
. 2017 May;
390(7):761-763.
PMID: 28474169
No abstract available.
5.
Michel-Reher M, Michel M
Naunyn Schmiedebergs Arch Pharmacol
. 2015 Aug;
388(10):1119-20.
PMID: 26278281
No abstract available.
6.
van Wieringen J, Michel-Reher M, Hatanaka T, Ueshima K, Michel M
Eur J Pharmacol
. 2013 Nov;
720(1-3):124-30.
PMID: 24183974
As no suitable radioligand exists for the detection of β3-adrenoceptors, we have explored the radioligand binding properties of a tritiated version of the selective β3-adrenoceptor antagonist L 748,337. Kinetic and...
7.
Michel-Reher M, Michel M
Naunyn Schmiedebergs Arch Pharmacol
. 2013 Jun;
386(10):843-51.
PMID: 23756578
β3-Adrenoceptors are resistant to agonist-induced desensitization in some cell types but susceptible in others including transfected human embryonic kidney (HEK) cells. Therefore, we have studied cellular and molecular changes involved...
8.
Wuest M, Witte L, Michel-Reher M, Propping S, Braeter M, Strugala G, et al.
World J Urol
. 2011 Feb;
29(2):149-55.
PMID: 21336600
Purpose: Combination therapy of male lower urinary tract symptoms with α(1)-adrenoceptor and muscarinic receptor antagonists attracts increasing interest. Propiverine is a muscarinic receptor antagonist possessing additional properties, i.e., block of...
9.
Frazier E, Michel-Reher M, van Loenen P, Sand C, Schneider T, Peters S, et al.
Eur J Pharmacol
. 2010 Dec;
654(1):86-91.
PMID: 21172342
Nebivolol is a selective β₁-adrenoceptor antagonist which, in addition, displays endothelium-dependent vasodilating properties in humans and other species. β₃-adrenoceptors have been proposed to be a molecular target of nebivolol-induced vasodilatation....
10.
Frazier E, Michel-Reher M, Sand C, Schneider T, Peters S, Michel M
Eur J Pharmacol
. 2008 Aug;
PMID: 18703044
This article has been withdrawn at the request of the authors. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found...